Drug-induced movement disorders: Emergencies and management

Neurologic Clinics

Volumn 30, Issue 1, 2012, Pages 309-320

  Robottom, Bradley J ^a   Shulman, Lisa M ^b   Weiner, William J ^b  

^a Durham Office   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Drug induced; Dystonia; Emergency; Movement disorders; Parkinsonism; Tremor

Indexed keywords

AMOXAPINE; ANTIHISTAMINIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BROMOCRIPTINE; BUSPIRONE; CARBIDOPA PLUS LEVODOPA; CLOZAPINE; CYPROHEPTADINE; DANTROLENE; DROPERIDOL; FENTANYL; LITHIUM; LYSERGIDE; METHYLPREDNISOLONE; METOCLOPRAMIDE; NEUROLEPTIC AGENT; OPIATE DERIVATIVE; PRAMIPEXOLE; PROCHLORPERAZINE; PROMETHAZINE; RASAGILINE; ROPINIROLE; SELEGILINE; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TETRABENAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTAN DERIVATIVE; TRYPTOPHAN; UNINDEXED DRUG; STREET DRUG;

BRAIN DEPTH STIMULATION; CLINICAL FEATURE; DIAGNOSTIC VALUE; DRUG MEGADOSE; DYSKINESIA; DYSTONIA; ELECTROCONVULSIVE THERAPY; EMERGENCY MEDICINE; EMERGENCY WARD; GENETIC SUSCEPTIBILITY; HUMAN; HYPERPYREXIA; INTENSIVE CARE UNIT; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSON DISEASE; PARKINSONISM; PARKINSONISM HYPERPYREXIA SYNDROME; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RHABDOMYOLYSIS; SEROTONIN SYNDROME; TREATMENT WITHDRAWAL; CHEMICALLY INDUCED DISORDER; EMERGENCY; TREMOR;

DYSKINESIA, DRUG-INDUCED; EMERGENCIES; HUMANS; STREET DRUGS; TREMOR;

EID: 84856245872     PISSN: 07338619     EISSN: 15579875     Source Type: Journal    
DOI: 10.1016/j.ncl.2011.09.007     Document Type: Review

References (87)

1. Movement disorder emergencies: diagnosis and treatment 2005, 1. Humana Press, Totowa (NJ). S.J. Frucht, S. Fahn (Eds.).
2. Delay J., Pichot P., Lemperiere T. Un neuroleptique majeur non phenothiazine et non reserpinique l'haloperidal dans le traitement des psychoses. Ann Med Pscyhol 1960, 118:145-152. [in French].
3. Shalev A., Munitz H. The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand 1986, 50:18-25.
4. Caroff S.N., Mann S.C. Neuroleptic malignant syndrome. Psychopharmacol Bull 1988, 24:25-29.
5. Shalev A., Hermesh H., Munitz H. Mortality from neuroleptic malignant syndrome. JClin Psychiatry 1989, 50:18-25.
6. Hasan S., Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry 1998, 115:1113-1116.
7. Caroff S.N., Mann S.C., Campbell E.C. Neuroleptic malignant syndrome. Adverse Drug React Bull 2001, 209:799-802.
8. Khan F.Y., Qusad M.J. Neuroleptic malignant syndrome. Neuroscience 2006, 11(2):104-106.
9. Petzinger G.M., Bressman S.B. Acase of tetrabenazine-induced neuroleptic malignant syndrome after prolonged treatment. Mov Disord 1997, 12(2):246-248.
10. Washington C., Haines K.A., Tam C.W. Amoxipine-induced neuroleptic malignant syndrome. DICP 1989, 23(9):713.
11. Gill J., Singh H., Nugent K. Acute lithium intoxication and neuroleptic malignant syndrome. Pharmacotherapy 2003, 23(6):811-815.
12. Levenson J.L. Neuroleptic malignant syndrome. Am J Psychiatry 1985, 142(10):1137-1145.
13. Gurrera R., Caroff S., Cohen A. Neuroleptic malignant syndrome diagnosis: an international consensus study using the Delphi technique. Eur Psychiatry 2010, 25(Suppl 1):949.
14. Caroff S.N., Mann S.C. Neuroleptic malignant syndrome. Med Clin North Am 1993, 77:202.
15. Kipps C.M., Fung V.S.C., Grattan-Smith P., et al. Movement disorder emergencies. Mov Disord 2005, 20(3):322-334.
16. Alexander P.J., Thomas R.M., Das A. Is risk of neuroleptic malignant syndrome increased in the postpartum period?. JClin Psychiatry 1998, 59(5):254-255.
17. Otani K., Horiuchi M., Kondo T., et al. Is the predisposition to neuroleptic malignant syndrome genetically transmitted. Br J Psychiatry 1991, 158(1):850-853.
18. Rosebush P., Anglin R., Richards C., et al. Neuroleptic malignant syndrome and acute phase response. JClin Psychopharmacol 2008, 28:459-461.
19. Berman B.D. Neuroleptic malignant syndrome: a review for neurohospitalists. The Neurohospitalist 2011, 1(1):41-47.
20. Rosenberg M.R., Green M. Neuroleptic malignant syndrome: review of response to therapy. Arch Intern Med 1989, 149:1927-1931.
21. Adnet P., Lestavel P., Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth 2000, 85:129-135.
22. Rosebush P.I., Stewart T.D., Gelenberg A.J. Twenty neuroleptic rechallenges afterneuroleptic malignant syndrome in 15 patients. JClin Psychiatry 1989, 50:295-298.
23. Caroff S.N., Mann S.C., Keck P.E. Specific treatment of the neuroleptic malignant syndrome. Biol Psychiatry 1998, 44:378-381.
24. Weiner W.J., Koller W.C., Perlik S., et al. Drug holiday and management of Parkinson disease. Neurology 1980, 30:1257-1261.
25. Sechi G., Tanda F., Mutani R. Fatal hyperpyrexia after withdrawal from levodopa. Neurology 1984, 34:249-251.
26. Friedman J.H., Feinberg S.S., Feldman R.G. Aneuroleptic malignant-like syndrome due to levodopa therapy withdrawal. JAMA 1985, 15:2792-2795.
27. Factor S.A. Fatal parkinsonism-hyperpyrexia syndrome in a Parkinson's disease patient while actively treated with deep brain stimulation. Mov Disord 2007, 22(1):148-153.
28. Ito T., Shibata K., Watanabe A., et al. Neuroleptic malignant syndrome following withdrawal of amantadine in a patient with influenza a encephalopathy. Eur J Pediatr 2001, 160(6):401.
29. Iwuagwu C.U., Riley D., Bonomo R.A. Neuroleptic malignant-like syndrome in an elderly patient caused by abrupt withdrawal of tolcapone, a catechol-O-methyl transferase inhibitor. Am J Med 2000, 108(6):517-518.
30. Reimer J., Kuhlmann A., Muller T. Neuroleptic malignant-like syndrome after rapid switch from bromocriptine to pergolide. Parkinsonism Relat Disord 2002, 9(2):115-116.
31. Kuno S., Mizuta E., Yamasaki S. Neuroleptic malignant syndrome in parkinsonian patients: risk factors. Eur Neurol 1997, 38:56-59.
32. Sato Y., Asoh T., Metoki N., et al. Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson's disease. JNeurol Neurosurg Psychiatry 2003, 74:574-576.
33. Factor SA, Weiner WJ. Movement disorders emergencies: adults and children. American Academy of Neurology, 61st Annual Meeting. Seattle, WA, April 25-May 2, 2009.
34. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991, 148:705-713.
35. Oates J.A., Sjoerdsma A. Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor. Neurology 1960, 10:1076-1078.
36. Mason P.J., Morris V.A., Balcezak T.J. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine 2000, 79:201-209.
37. Robottom B.J. Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease. Patient Prefer Adherence 2011, 5:57-64.
38. Alkhatib A.A., Peterson K.A., Tuteja A.K. Serotonin syndrome as a complication of fentanyl sedation during esophagogastroduodenoscopy. Dig Dis Sci 2010, 55:215-216.
39. Kirschner R., Donovan J.W. Serotonin syndrome precipitated by fentanyl during procedural sedation. JEmerg Med 2010, 38(4):477-480.
40. Radomski J.W., Dursun S.M., Reveley M.A., et al. An exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteria. Med Hypotheses 2000, 55(3):218-224.
41. Hall M., Buckley N. Serotonin syndrome. Aust Prescr 2003, 26:62-63.
42. Mills K.C. Serotonin syndrome: a clinical update. Crit Care Clin 1997, 13(4):763-783.
43. Okamoto N., Sakamoto K., Nagafusa Y., et al. Electroconvulsive therapy as a potentially effective treatment for severe serotonin syndrome: two case reports. JClin Psychopharmacol 2010, 30(3):350-352.
44. Diederich N.J., Goetz C.G. Drug-induced movement disorders. Neurol Clin 1998, 16(1):125-139.
45. Pierre J.M. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf 2005, 28(3):191-208.
46. van Harten P.N., Hock H.W., Kahn R.S. Acute dystonia induced by drug treatment. BMJ 1999, 319:623-626.
47. Lutz E.G. Neuroleptic-induced akathisia and dystonia triggered by alcohol. JAMA 1976, 236:2422-2423.
48. Freed E. Alcohol-triggered neuroleptic-induced tremor, rigidity, and dystonia. Med J Aust 1981, 2:44-45.
49. Campbell D. The management of acute dystonic reactions. Aust Prescriber 2001, 24:19-20.
50. Lange R.A., Hillis L.D. Cardiovascular complications of cocaine use. NEngl J Med 2001, 345:351-358.
51. Brust J.C.M. Substance abuse and movement disorders. Mov Disord 2010, 25:2010-2020.
52. Rylander G. Psychosis and the punding and choreiform syndromes in addictions to central stimulant drugs. Psychiatry Neurol Neurchir 1972, 75:203-212.
53. Derlet R.W., Alberston T.E. Emergency department presentation of cocaine intoxication. Ann Emerg Med 1989, 18:182-186.
54. Brody S.L., Slovis C.M., Wrenn K.D. Cocaine-related medical problems: consecutive series of 233 patients. Am J Med 1990, 88:325-331.
55. Randrup A., Munkvad J. Stereotyped activities produced by amphetamine in several species and man. Psychopharmacologia 1967, 11:300-310.
56. Daras M., Koppel B.S., Atos-Radzion E. Cocaine-induced choreoathetoid movements (crack-dancing). Neurology 1994, 44:751-752.
57. Choy-Kwong M., Lipton R.B. Dystonia related to cocaine withdrawal: a case report and pathogenic hypothesis. Neurology 1989, 39:996-997.
58. Kumor K. Cocaine withdrawal dystonia. Neurology 1990, 40:863-864.
59. Weiner W.J., Rubinstein A., Lewin B., et al. Cocaine-induced persistent dyskinesias. Neurology 2001, 56:964-965.
60. Lundh H., Tunving K. An extrapyramidal choreiform syndrome caused by amphetamine addiction. JNeurol Neurosurg Psychiatry 1981, 44:728-730.
61. Pascual-Leone A., Dhuna A. Cocaine-associated multifocal tics. Neurology 1990, 40:999-1000.
62. Factor S.A., Sanchez-Ramos J.R., Weiner W.J., et al. Cocaine and Tourette's syndrome. Ann Neurol 1988, 23:423-424.
63. Golden G.S. Gilles de la Tourette's syndrome following amphetamine administration. Dev Med Child Neurol 1976, 16:76-77.
64. Kurlan R. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 2001, 58:527-536.
65. Brown C., Osterloh J. Multiple severe complications from recreational ingestion of MDMA (ecstasy). JAMA 1987, 258:780-781.
66. Hinkelbein J., Gabel A., Volz M., et al. Suicide attempt with high dose ecstasy. Anesthetist 2003, 52:51-54.
67. Regenthal R., Kruger M., Rudolf K., et al. Survival after massive "ecstasy" (MDMA) ingestion. Intensive Care Med 1999, 25:640-641.
68. Ames D., Wirshing W.C. Ecstasy, the serotonin syndrome, and neuroleptic malignant syndrome-a possible link?. JAMA 1993, 269:869-870.
69. Grunau B.E., Wiens M.O., Brubacher J.R. Dantrolene in the treatment of MDMA-related hyperpyrexia: a systematic review. CJEM 2010, 12:435-442.
70. Lauterbach E.C. Hiccup and apparent myoclonus after hydrocodone: a review of the opiate-related hiccup and myoclonus literature. Clin Neuropharmacol 1999, 22:87-92.
71. Hershey L.A. Meperidine and central neurotoxicity. Ann Intern Med 1983, 98:548-549.
72. Kaiko R.F., Folwy K.M., Grabinski P.Y., et al. Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol 1983, 13:180-185.
73. Dougherty J.A., Young H., Shafi T. Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine. Ann Pharmacol 2002, 36:1647-1648.
74. Tissot T.A. Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use. Anesthesiology 2003, 98:1511-1512.
75. Latta K.S., Ginsberg B., Barkin R.L. Meperidine: a critical review. Am J Ther 2002, 9:53-68.
76. Ahlskog J.E., Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001, 16(3):448-458.
77. Factor S.A., Molho E.S. Emergency department presentations of patients with Parkinson's disease. Am J Emerg Med 2000, 18(2):209-215.
78. Chou S.M., Gutmann L. Deteriorating parkinsonism and subdural hematomas. Neurology 2001, 57:1295.
79. Weiner W.J., Goetz C.G., Nausieda P.A., et al. Respiratory dyskinesias: extrapyramidal dysfunction and dyspnea. Ann Intern Med 1978, 88:327-331.
80. Pahwa R., Factor S.A., Lyons K.E., et al. Practice parameter: treatment of Parkinson disease motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006, 66:983-995.
81. Aarsland D., Larsen J.P., Tandberg E., et al. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. JAm Geriatr Soc 2000, 48:938-942.
82. Robottom B.J., Weiner W.J. Parkinson's disease dementia. Curr Psychiatry Rev 2009, 5(3):218-225.
83. Giladi N., Treves T.A., Paleacu D., et al. Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease. JNeural Transm 2000, 107(1):59-71.
84. Mosimann U.P., Rowan E.N., Partington C.E., et al. Characteristics of visual hallucinations in Parkinson disease dementia and dementia with Lewy bodies. Am J Geriatr Psychiatry 2006, 14:153-160.
85. Friedman J.H., Factor S.A. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 2000, 15:201-211.
86. Miyasaki J.M., Shannon K., Voon V., et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review). Neurology 2006, 66:996-1002.
87. Robottom B.J., Weiner W.J., Factor S.A. Movement disorders emergencies part 1: hypokinetic disorders. Arch Neurol 2011, 68:567-572.